EP2575777A1 - Formulation comprenant du cefpodoxime proxétil et de l'acide clavulanique - Google Patents
Formulation comprenant du cefpodoxime proxétil et de l'acide clavulaniqueInfo
- Publication number
- EP2575777A1 EP2575777A1 EP11770579.8A EP11770579A EP2575777A1 EP 2575777 A1 EP2575777 A1 EP 2575777A1 EP 11770579 A EP11770579 A EP 11770579A EP 2575777 A1 EP2575777 A1 EP 2575777A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical composition
- composition according
- clavulanic acid
- microcrystalline cellulose
- cefpodoxime proxetil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Definitions
- the present invention relates to pharmaceutical compositions comprising cefpodoxime proxetil and clavulanic acid and/or derivatives thereof as the active agents.
- Cefpodoxime proxetil (Formula I), chemical name of which is pivaloyloxymethyl 7-[2-(2- amino-thiazole-4-yl]-2-(syn)-methoxyimino-acetamido]-3-methoxymethyl-3-cefem-4- carboxylate, was first disclosed in the patent numbered EP0049118.
- Clavulanic acid is a beta-lactamase inhibitor illustrated in Formula 2.
- Clavulanic acid and derivatives thereof are known as the beta-lactamase inhibitors which withstand the beta-lactamase-originated resistance mechanism by suppressing the activity of beta-lactamase enzymes.
- EP0593573 comprises a formulation relating to suspension forms of beta-lactam antibiotics and beta lactamase inhibitors.
- suspension forms are not preferred much as they have the potential of high and/or uncontrolled dose intake; there appear problems in their physical and chemical stability; they have high manufacture costs and they cause problems in use and carrying.
- the inventors have aimed to develop stable oral pharmaceutical formulations which comprise cefpodoxime proxetil and clavulanic acid derivatives thereof together and eliminate the low solubility problem of cefpodoxime proxetil.
- the present invention relates to stable pharmaceutical compositions with good solubility characteristics in which cefpodoxime proxetil and clavulanic acid are formulated together. It has surprisingly been seen that when the pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid wherein
- each one of the cellulose-based disintegrants is present in an amount more than 7% by weight with respect to the weight of the unit dose is developed, dissolution of the cefpodoxime proxetil increases and dissolution time of the composition decreases.
- the first aspect of the present invention is the pharmaceutical compositions comprising cefpodoxime proxetil and clavulanic acid as the active agents wherein a combination of croscarmellose and microcrystalline cellulose is used as the disintegrant and each one of the cellulose-based disintegrants is present in an amount more than 7% with respect to the unit dose.
- Cefpodoxime proxetil that can be used in the pharmaceutical composition of the present invention can be in the form of its solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or in free base form and/or a combination thereof.
- Clavulanic acid that can be used in the pharmaceutical composition of the present invention can be in the form of its solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free base form and/or a combination thereof.
- potassium clavulanate is used in the present invention.
- Croscarmellose sodium used in the pharmaceutical composition according to the present invention is present in an amount more than 7%, preferably in the range of 8-15%, more preferably in the range of 9-12% with respect to unit dose amount. Although the use of croscarmellose sodium in this specified amount is more than the amount disclosed in the prior art, the inventors have found that the dissolution rate of the composition increases in contrast to expectations.
- compositions comprising cefpodoxime proxetil and clavulanic acid or its derivatives wherein croscarmellose sodium is preferably used in an amount in the range of 8-15%, more preferably in an amount in the range of 9-12% by weight with respect to the weight of the unit dose.
- Microcrystalline cellulose used in the pharmaceutical composition according to the present invention is present in an amount more than 7%, preferably in the range of 8-15%, more preferably in the range of 9-13% with respect to unit dose amount.
- the inventors have found that the dissolution time reduces by 60% in the case that microcrystalline cellulose is used in said amount.
- compositions comprising cefpodoxime proxetil and clavulanic acid or its derivatives wherein microcrystalline cellulose is preferably used in an amount in the range of 8-15%, more preferably in an amount in the range of 9-13% by weight with respect to the weight of the unit dose.
- each cellulose-based disintegrant in an amount more than 7% with respect to the unit dose has an important effect on both the increase of dissolution of cefpodoxime proxetil and decrease in dissolution time of the composition comprising cefpodoxime proxetil and clavulanic acid.
- the inventors have observed that an optimum particle size of the cellulose-based disintegrant used in the composition of the present invention has a considerable effect on the disintegration and dissolution of the composition. They have found that when the particle size of microcrystalline cellulose used in the present invention is less than 100 ⁇ , preferably in the range of 30-90 ⁇ and more preferably in the range of 40-60 ⁇ , the dissolution of the composition increases and also dissolution time decreases.
- compositions comprising cefpodoxime proxetil and clavulanic acid or its derivatives wherein microcrystalline cellulose with a particle size less than 100 ⁇ , preferably in the range of 30- 90 ⁇ and more preferably in the range of 40-60 ⁇ is used in the disintegrant combination.
- the formulation of the present invention can comprise various excipients such as, but not limited to, glidants, lubricants, diluents, surfactants and optionally coating agents.
- the glidant that can be used in the pharmaceutical composition of the present invention can be selected from, but not limited to, a group comprising magnesium silicate, silicon dioxide, starch, talc, tribasic calcium phosphate or combinations thereof.
- the lubricant that can be used in the pharmaceutical composition of the present invention can be selected from, but not limited to, a group comprising calcium stearate, magnesium stearate, polyoxyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, talc, sodium benzoate or combinations thereof.
- magnesium stearate is used as the lubricant in the pharmaceutical composition of the present invention.
- the diluent that can be used in the pharmaceutical composition of the present invention can be selected from, but not limited to, a group comprising calcium carbonate, calcium sulfate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch, xylitol or combinations thereof.
- the surfactant that can be used in the pharmaceutical composition of the present invention can be selected from, but not limited to, a group comprising docusate sodium, sorbitan esters, cetrimide and sodium lauryl sulfate.
- sodium lauryl sulfate is preferably used as the surfactant.
- the pharmaceutical composition of the present invention can comprise 20-800 mg cefpodoxime proxetil or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an equal amount.
- the pharmaceutical composition of the present invention can comprise 50-500 mg clavulanic acid or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an equal amount.
- Clavulanic acid and its derivatives e.g. potassium clavulanate
- potassium clavulanate in the pharmaceutical composition is preferably used with a humectant in the ratio of 1 : 1.
- colloidal silica for instance colloidal silica anhydrous, for example Aerosil® 200, magnesium trisilicate, cellulose powder, Cabosil®, magnesium oxide, calcium silicate, Syloid®, starch, microcrystalline cellulose, talc can be used as the humectant.
- potassium clavulanate is used with microcrystalline cellulose preferably in the ratio of 1 : 1.
- the pharmaceutical composition of the present invention can comprise 5-60% cefpodoxime proxetil in proportion to total weight of unit dose or pharmaceutically acceptable solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms thereof.
- the pharmaceutical composition of the present invention can comprise 5-50% clavulanic acid in proportion to total weight of unit dose or pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an equal amount.
- the pharmaceutical composition of the present invention can comprise 5-60% cefpodoxime proxetil; 5-50% potassium clavulanate; 0,5-5% glidant; 0,1-5% lubricant; 0,1-25% disintegrant and/or disintegrants; 1-30% diluent; 0,1-5% surfactant and optionally coating agent of 1-5% of the core weight.
- the pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid prepared according to the present invention can be in conventional tablet, film coated tablet, sachet or capsule form.
- the present invention relates to processes for preparation of pharmaceutical compositions comprising pharmaceutically acceptable excipients in addition to cefpodoxime proxetil and clavulanic acid or its derivatives as the active agents.
- the process of the present invention comprises the steps of granulating the active agent cefpodoxime proxetil and clavulanic acid or its derivatives by conventional wet and/or dry granulation methods; or powdering cefpodoxime proxetil, clavulanic acid derivatives and other excipients after mixing them by dry blending method and - compressing the pharmaceutical composition of the present invention in tablet form and optionally coating the tablets with a coating agent in the case that the product is developed in tablet form and/or,
- Another aspect of the present invention is that the formulation prepared according to said invention is used in the treatment of diseases related with infections caused by gram negative and gram positive bacteria.
- the pharmaceutical composition prepared according to the present invention is used in the production of a medicament so as to be used in upper respiratory infections such as ear, nose, throat, otitis media, sinusitis, tonsillitis, pharyngitis; lower respiratory tract infections such as pyelonephritis, cystitis and urethritis; skin or soft tissue infections such as froncle, pyoderma, impetigo; in the treatment and prophylaxis of gonorrhea and lyme diseases.
- upper respiratory infections such as ear, nose, throat, otitis media, sinusitis, tonsillitis, pharyngitis
- lower respiratory tract infections such as pyelonephritis, cystitis and urethritis
- skin or soft tissue infections such as froncle, pyoderma, impetigo
- in the treatment and prophylaxis of gonorrhea and lyme diseases in the production of a medicament so as to be used in upper respiratory infections such as
- composition of the present invention can be prepared as described below, but not limited to the examples given.
- EXAMPLE 1 Formulation and process for preparation of film tablet comprising cefpodoxime proxetil and potasium clavulanate
- a process for preparation of pharmaceutical compositions is composed of the steps of mixing and compressing cefpodoxime proxetil, the disintegrant and the diluent and then sieving them; adding the surfactant, potassium clavulanate: avicel, disintegrant, glidant and lubricant into the granules obtained and mixing them; and then compressing tablets of the mixture obtained and coating the tablets with coating material.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne des compositions pharmaceutiques comprenant du cefpodoxime proxétil, de l'acide clavulanique et/ou ses dérivés en tant qu'agents actifs.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR201004467 | 2010-06-03 | ||
PCT/TR2011/000148 WO2011152808A1 (fr) | 2010-06-03 | 2011-06-02 | Formulation comprenant du cefpodoxime proxétil et de l'acide clavulanique |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2575777A1 true EP2575777A1 (fr) | 2013-04-10 |
Family
ID=44802368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11770579.8A Withdrawn EP2575777A1 (fr) | 2010-06-03 | 2011-06-02 | Formulation comprenant du cefpodoxime proxétil et de l'acide clavulanique |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2575777A1 (fr) |
WO (1) | WO2011152808A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013151517A1 (fr) * | 2012-04-04 | 2013-10-10 | Mahmut Bilgic | Formulations en comprimés comprenant du cefpodoxime proxétil et de l'acide clavulanique |
WO2014123500A1 (fr) * | 2013-02-11 | 2014-08-14 | Bilgiç Mahmut | Formulations pharmaceutiques contenant du cefpodoxime proxétil et de l'acide clavulanique |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4486425A (en) | 1980-09-30 | 1984-12-04 | Sankyo Company Limited | 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates |
GB9114950D0 (en) | 1991-07-11 | 1991-08-28 | Smithkline Beecham Plc | Pharmaceutical formulation |
US5837292A (en) * | 1996-07-03 | 1998-11-17 | Yamanouchi Europe B.V. | Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug |
WO2004006917A1 (fr) * | 2002-07-16 | 2004-01-22 | Ranbaxy Laboratories Limited | Comprimes dispersibles pour administration par voie orale |
AU2005204017B2 (en) * | 2004-01-06 | 2008-01-31 | Panacea Biotec Ltd. | Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer |
ZA200807943B (en) * | 2006-03-24 | 2009-11-25 | Panacea Biotec Ltd | Antibiotic compositions of modified release and process of production thereof |
-
2011
- 2011-06-02 EP EP11770579.8A patent/EP2575777A1/fr not_active Withdrawn
- 2011-06-02 WO PCT/TR2011/000148 patent/WO2011152808A1/fr active Application Filing
Non-Patent Citations (2)
Title |
---|
None * |
See also references of WO2011152808A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011152808A1 (fr) | 2011-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2528594B1 (fr) | Formulations effervescentes contenant de la céphalosporine de deuxième génération | |
EP3417861B1 (fr) | Composition pharmaceutique contenant un inhibiteur de janus kinase (jak) ou un sel pharmaceutiquement acceptable de celui-ci | |
EP2568959A2 (fr) | Formulations comprenant une céphalosporine et un acide clavulanique de troisième génération | |
WO2012060788A1 (fr) | Formulations de céphalosporines avec teneur en humidité contrôlée | |
EP2366379A1 (fr) | Forme de cefdinir avec taux de dissolution amélioré | |
WO2011142730A1 (fr) | Composition pharmaceutique comprenant la céfixime et un composé dérivé de l'acide clavulanique | |
EP2566449B1 (fr) | Compositions pharmaceutiques comprenant du ceftibutène | |
EP2575777A1 (fr) | Formulation comprenant du cefpodoxime proxétil et de l'acide clavulanique | |
WO2012060786A2 (fr) | Formulations de proxétil cefpodoxime comprenant un agent de viscosité | |
US20130129791A1 (en) | Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof | |
WO2011152805A2 (fr) | Composition pharmaceutique comprenant de l'acide clavulanique et du cefpodoxime proxétil | |
EP2833874A1 (fr) | Formulations de capsule comprenant du ceftibutène | |
EP2608776A2 (fr) | Préparations de cefpodoxime proxétil | |
WO2011093828A2 (fr) | Formes posologiques solides comprenant du cefprozil | |
EP2566451B1 (fr) | Composition pharmaceutique contentant de cefditoren pivoxil | |
WO2012060787A1 (fr) | Comprimés contenant du cefdinir | |
WO2012060791A2 (fr) | Procédé de production de compositions pharmaceutiques comprenant du cefdinir | |
WO2014123500A1 (fr) | Formulations pharmaceutiques contenant du cefpodoxime proxétil et de l'acide clavulanique | |
EP2833873A1 (fr) | Formulations en comprimés pelliculés comprenant du céfuroxime axétil et de l'acide clavulanique | |
WO2012060792A1 (fr) | Compositions pharmaceutiques comprenant au minimum 6% en poids de délitants | |
WO2012060793A2 (fr) | Procédé de préparation de formulations de cefdinir | |
EP2833872A1 (fr) | Formulations en comprimés comprenant du cefpodoxime proxétil et de l'acide clavulanique | |
WO2006100574A1 (fr) | Granules de cefditoren pivoxil amorphe et procedes d'elaboration correspondants | |
WO2012078121A2 (fr) | Forme posologique orale solide comprenant cefdinir | |
EP2663289A2 (fr) | Préparations de cefpodoxime proxétil comprenant un agent régulateur de goût |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20121231 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20160310 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20180207 |